High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children

Journal of Infectious Diseases

Volumn 210, Issue 11, 2014, Pages 1755-1762

  Malm, Maria ^a   Uusi Kerttula, Hanni ^a   Vesikari, Timo ^a,b   Blazevic, Vesna ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antibodies; Blocking; Children; Norovirus; Protection

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; BLOCKING ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHILD HEALTH; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; NOROVIRUS INFECTION; PRIORITY JOURNAL; SEROCONVERSION; VIRAL GASTROENTERITIS; VIRUS LIKE AGENT; AGE; BLOOD; CALICIVIRUS INFECTION; GASTROENTERITIS; GENETICS; IMMUNOLOGY; INFANT; NEWBORN; NOROVIRUS; PRESCHOOL CHILD;

AGE FACTORS; ANTIBODIES, BLOCKING; ANTIBODIES, VIRAL; CALICIVIRIDAE INFECTIONS; CHILD; CHILD, PRESCHOOL; GASTROENTERITIS; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; NOROVIRUS;

EID: 84922310933     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu361     Document Type: Article

References (45)

1. Pang XL, Honma S, Nakata S, Vesikari T. Human caliciviruses in acute gastroenteritis of young children in the community. J Infect Dis 2000; 181(suppl 2):S288-94.
2. Rasanen S, Lappalainen S, Salminen M, Huhti L, Vesikari T. Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. Eur J Pediatr 2011; 170:1413-8.
3. Puustinen L, Blazevic V, Salminen M, Hamalainen M, Rasanen S, Vesikari T. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand J Infect Dis 2011; 43:804-8.
4. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224-31.
5. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011; 30: S1-5.
6. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-30.
7. Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013; 172:739-46.
8. Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011; 29:8126-33.
9. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk virus illness. N Engl J Med 2011; 365:2178-87.
10. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158:2059-68.
11. Rackoff LA, Bok K, Green KY, Kapikian AZ. Epidemiology and evolution of rotaviruses and noroviruses from an archival WHO Global Study in Children (1976-79) with implications for vaccine design. PLoS One 2013; 8:e59394.
12. Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants. J Clin Virol 2013; 56:185-93.
13. van Beek J, Ambert-Balay K, Botteldoorn N, et al. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012. 2013; 18:8-9.
14. Lindesmith LC, Donaldson EF, Lobue AD, et al. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
15. Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013; 208:1877-87.
16. Eden JS, Tanaka MM, Boni MF, Rawlinson WD, White PA. Recombination within the pandemic norovirus GII.4 lineage. J Virol 2013; 87:6270-82.
17. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol 2011; 19:233-40.
18. Zakikhany K, Allen DJ, Brown D, Iturriza-Gomara M. Molecular evolution of GII-4 Norovirus strains. PLoS One 2012; 7:e41625.
19. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
20. Cannon JL, Lindesmith LC, Donaldson EF, Saxe L, Baric RS, Vinje J. Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol 2009; 83:5363-74.
21. Vega E, Barclay L, Gregoricus N, Williams K, Lee D, Vinje J. Novel surveillance network for norovirus gastroenteritis outbreaks, United States. Emerg Infect Dis 2011; 17:1389-95.
22. Nurminen K, Blazevic V, Huhti L, et al. Prevalence of norovirus GII-4 antibodies in Finnish children. J Med Virol 2011; 83:525-31.
23. Ryder RW, Singh N, Reeves WC, Kapikian AZ, Greenberg HB, Sack RB. Evidence of immunity induced by naturally acquired rotavirus and Norwalk virus infection on two remote Panamanian islands. J Infect Dis 1985; 151:99-105.
24. Black RE, Greenberg HB, Kapikian AZ, Brown KH, Becker S. Acquisition of serum antibody to Norwalk Virus and rotavirus and relation to diarrhea in a longitudinal study of young children in rural Bangladesh. J Infect Dis 1982; 145:483-9.
25. Talal AH, Moe CL, Lima AA, et al. Seroprevalence and seroincidence of Norwalk-like virus infection among Brazilian infants and children. J Med Virol 2000; 61:117-24.
26. Matsui SM, Greenberg HB. Immunity to calicivirus infection. J Infect Dis 2000; 181(suppl 2):S331-5.
27. Donaldson EF, Lindesmith LC, Lobue AD, Baric RS. Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol 2010; 8:231-41.
28. Debbink K, Lindesmith LC, Donaldson EF, Baric RS. Norovirus immunity and the great escape. PLoS Pathog 2012; 8:e1002921.
29. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005; 79:2900-9.
30. Rockx B, Baric RS, de Grijs I, Duizer E, Koopmans MP. Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol 2005; 77:439-46.
31. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. J Infect Dis 2003; 187:187-93.
32. Nakata S, Chiba S, Terashima H, Yokoyama T, Nakao T. Humoral immunity in infants with gastroenteritis caused by human calicivirus. J Infect Dis 1985; 152:274-9.
33. Lew J, Valdesuso J, Vesikari T, et al. Detection of Norwalk virus or Norwalk-like virusinfections in Finnish infants and young children 1994. J Infect Dis 1994; 169:1364-7.
34. Blacklow NR, Cukor G, Bedigian MK, et al. Immune response and prevalence of antibody to Norwalk enteritis virus as determined by radioimmunoassay. J Clin Microbiol 1979; 10:903-9.
35. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990; 161:18-21.
36. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8.
37. Huhti L, Blazevic V, Nurminen K, Koho T, Hytonen VP, Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Arch Virol 2010; 155:1855-8.
38. Huhti L, Tamminen K, Vesikari T, Blazevic V. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography. Arch Virol 2013; 158: 933-42.
39. Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013; 8:e70409.
40. Tamminen K, Huhti L, Koho T, et al. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2012; 135:89-99.
41. Sai L, Sun J, Shao L, Chen S, Liu H, Ma L. Epidemiology and clinical features of rotavirus and norovirus infection among children in Ji'nan, China. Virol J 2013; 10:302, 422X-10-302.
42. Muhsen K, Kassem E, Rubinstein U, et al. Incidence and characteristics of sporadic norovirus gastroenteritis associated with hospitalization of children less than 5 years of age in Israel. Pediatr Infect Dis J 2013; 32:688-90.
43. Bucardo F, Nordgren J, Carlsson B, et al. Pediatric norovirus diarrhea in Nicaragua. J Clin Microbiol 2008; 46:2573-80.
44. Iritani N, Seto T, Hattori H, et al. Humoral immune responses against norovirus infections of children. J Med Virol 2007; 79:1187-93.
45. Wyatt RG, Dolin R, Blacklow NR, et al. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974; 129:709-14.